Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that als...
Κύριοι συγγραφείς: | Sandercock, P, Warlow, C, Bamford, J, Peto, R, Starkey, I |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
1986
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
ανά: Turpie AGG
Έκδοση: (2014-03-01) -
A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation
ανά: Andrei Viktorovich Fonyakin, κ.ά.
Έκδοση: (2012-09-01) -
Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
ανά: Paula Tiili, κ.ά.
Έκδοση: (2021-01-01) -
Old and new oral anticoagulants for secondary stroke prevention in atrial fibrillation
ανά: Tommaso Sacquegna, κ.ά.
Έκδοση: (2015-12-01) -
Prevalence of oral anticoagulation in atrial fibrillation
ανά: Eduardo Bartholomay, κ.ά.
Έκδοση: (2014-09-01)